Viking Therapeutics
Logotype for Viking Therapeutics Inc

Viking Therapeutics (VKTX) investor relations material

Viking Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Viking Therapeutics Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

VK2735 maintenance results

  • At Week 21, weekly VK2735 produced 16.3%–18.7% weight loss across dose groups; the 17.5 mg cohort lost 17.8% (n=118), with no plateau observed.

  • After switching from weekly dosing, participants maintained up to 96.7% of Week 21 weight loss with every-other-week dosing and up to 90.2% with monthly dosing through Week 33; placebo participants regained ~40% of initial weight loss by Week 12.

  • Continued 17.5 mg weekly dosing produced 21.7% weight loss from baseline at Week 33, with no plateau observed.

  • Maintenance-phase GI adverse-event rates were similar to placebo, with low GI event rates after titration; early discontinuation was 3% with every-other-week and 5% with monthly dosing.

  • ApoB, non-HDL cholesterol and triglyceride effects tracked weight loss and remained consistent through maintenance.

Maintenance studies and dosing options

  • Part 2 evaluates transition from 17.5 mg weekly subQ to daily oral doses of 10–55 mg; a second study adds six higher-dose subQ arms for every-other-week and monthly dosing, with results expected in 2027 and around mid-year, respectively.

  • Monthly dosing retention was 90%; 35 mg monthly is being explored in a VANQUISH extension, with data intended for conference presentations and potential label language.

  • Potential maintenance options include weekly, every-other-week and monthly dosing, or transition from injection to oral therapy; oral maintenance targets retaining at least 75% of initial weight loss, particularly at mid-to-high doses.

  • A study switching patients from existing injectable treatments to VK2735 is considered worthwhile but is not planned near term.

  • Longer follow-up is planned in VANQUISH extensions through 52 weeks.

Phase 3 programs and market opportunity

  • VANQUISH-1 and VANQUISH-2 evaluate weekly subcutaneous VK2735 for 78 weeks; enrollment completed in 4Q25 and 1Q26, respectively, with data expected in 2H27.

  • SUNRISE-1 and SUNRISE-2 evaluate daily oral VK2735 for 68 weeks in obesity and obesity with diabetes; both began in 4Q26, target 560 participants each, and are expected to report data in 2028.

  • Four Phase 3 trials are underway; first Phase 3 data are targeted for H2 2027.

  • The obesity market is projected to exceed $150B by 2035, with a stated 16% CAGR; VK2735 is positioned for oral and injectable use and potential entry as the third obesity franchise.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Viking Therapeutics earnings date

Logotype for Viking Therapeutics Inc
38th Annual Healthcare Conference2 Dec, 2026
Viking Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Viking Therapeutics earnings date

Logotype for Viking Therapeutics Inc
38th Annual Healthcare Conference2 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company utilizes small-molecule drug technology to target conditions such as liver diseases, muscle disorders, and other chronic illnesses. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.